Received Jul 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Headache; Injection site pain; Body aches; This non-serious case was reported by a consumer and described the occurrence of injection site pain in a 51-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included major depression, mood disorder, normal thyroid function, hypogonadism male and insomnia. Concomitant products included venlafaxine, desvenlafaxine succinate monohydrate (Pristiq), quetiapine fumarate (Seroquel), testosterone cipionate and levothyroxine. On 15-JUL-2025, the patient received Shingrix. On 15-JUL-2025, less than a day after receiving Shingrix, the patient experienced injection site pain (Verbatim: Injection site pain) and general body pain (Verbatim: Body aches). On 16-JUL-2025, the patient experienced headache (Verbatim: Headache). The outcome of the injection site pain, general body pain and headache were not resolved. It was unknown if the reporter considered the injection site pain, general body pain and headache to be related to Shingrix. It was unknown if the company considered the injection site pain, general body pain and headache to be related to Shingrix. Additional Information: GSK Receipt Date: 16-JUL-2025 The reporter reported that the patient received Shingrix vaccine and experienced injection site pain, headache, body ache and was using gym equipment 6 hours after injection. The symptoms were treated.
Hypogonadism male; Insomnia; Major depression; Mood disorder; Normal thyroid function
Venlafaxine; Seroquel; Testosterone cipionate; Levothyroxine; Pristiq